{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:17Z","timestamp":1794002117084,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtho.2025.10.016","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:51:30Z","timestamp":1761789090000},"page":"103509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Fuentes","family":"Pradera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeen","family":"Mekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnoush","family":"Safavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelumka","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zavodovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane M.","family":"J\u00fcrgensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.10.016_bib1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.21037\/jtd.2018.03.15","article-title":"Updated statistics of lung and bronchus cancer in United States (2018)","volume":"10","author":"Boloker","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.10.016_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.10.016_bib3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib4","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO-24-02786","article-title":"Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2024.3","volume":"43","author":"Leighl","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib5","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.10.016_bib6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/cancers16040744","article-title":"Tumor characteristics and treatment responsiveness in pembrolizumab-treated non-small cell lung carcinoma","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2025.10.016_bib9","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van der Welle","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2025.10.016_bib11","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2025.10.016_bib12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib13","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-24-2523","article-title":"Sacituzumab govitecan in patients with relapsed\/refractory advanced head and neck squamous cell carcinoma: results from the phase II TROPiCS-03 basket study","volume":"31","author":"Michel","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.016_bib16","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.10.016_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-5002(00)00181-1","article-title":"Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis","volume":"31","author":"Khuder","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.10.016_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/tc.2007.022582","article-title":"Comparison of aspects of smoking among the four histological types of lung cancer","volume":"17","author":"Kenfield","year":"2008","journal-title":"Tob Control"},{"key":"10.1016\/j.jtho.2025.10.016_bib21","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","article-title":"Clinicopathologic features of advanced squamous NSCLC","volume":"11","author":"Socinski","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib22","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321555","article-title":"Trop-2 expression in non-small cell lung cancer","volume":"20","author":"Kuo","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2025.10.016_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB260","article-title":"Abstract LB260: Potential prognostic\/predictive biomarkers for sacituzumab govitecan in EVOKE-01","volume":"85","author":"Garassino","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.016_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB399","article-title":"Abstract LB399: Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +\/- carboplatin in the EVOKE-02 study of non-small cell lung cancer","volume":"85","author":"Patel","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.10.016_bib27","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.10.016_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.780379","article-title":"Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases","volume":"11","author":"Tan","year":"2022","journal-title":"Front Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425028904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:27:34Z","timestamp":1778819254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425028904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1556086425028904"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.016","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103509"}}